EUVIMEDEUVIMED entdecken
Crossref

The utility of genomics and functional imaging to predict sunitinib pharmacokinetics and pharmacodynamics: The predict SU study

Michael Michael iD, Guy C Toner, Vinod Ganju, Emma Link, Mick Thompson, Anetta Matera, Rodney J Hicks, Ian Campbell, Simone Rowley, Christos S Karapetis, Matthew Burge, David W Pook

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70431 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Michael Michael und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Sunitinib, Liver, Kidney Neoplasms, Antineoplastic Agents. Die Arbeit nennt 49 Literaturangaben. Gefördert von: National Health and Medical Research Council, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Sunitinib has marked pharmacokinetic (PK) and pharmacodynamic (PD) interpatient variability. This study evaluated the utility of extensive excretory/metabolic/PD pharmacogenomics (PGx) with hepatic functional imaging (HNI) to explore their associations with sunitinib PK/PD (toxicity/response) and progression‐free survival (PFS), respectively.

Methods

Eligible patients (pts) suitable for sunitinib therapy. At baseline: (i) PGx: blood analysed by the Affymetrix DMET™ Plus Array (1936 variants/225 genes) and Sanger sequencing (HNF1A, FLT3, VEGFR2, VEGFR3, RET, PDGFRα, TNFα). (ii) HNI: pts given IV 800 MBq 99m Tc‐MIBI, imaging data analysed for hepatic extraction/excretion parameters (CL HNI , T 1/2‐HNI , 1hRET, HEF, T d1/2 ). In cycles 1 and 2, bloods taken for sunitinib parent (SU), metabolite (SU12662) and total SU (metabolite + parent) PK. Associations evaluated between (i) HNI parameters and (2) PGx, with sunitinib PK, toxicity/response and PFS.

Results

N = 15 pts. The two most significant associations in either direction between PGx variants or HNI parameters ( p < .05) for: (i) PK included: (a) SU logAUC 0–14days with HEF, ATP7B (rs1801246) and UGT8 (rs4148254); (b) SU logAUC 0–28days , with T d1/2 , SLC15A1 (rs8187832) and SLC10A2 (rs188096); (c) SU12662 logAUC 0–14days with HEF, ABCC3 (rs11568591), PPARD (rs1003973) and SLC15A1 (rs8187840); and (d) SU12662 logAUC 0–28days with SULT1A2 (rs1059491) and SLC10A2 (rs188096). (ii) Toxicity: (a) Diarrhoea grade 1+ with HEF, VEFGR3 (rs307826) and AKAP9 (rs7785971); (b) ≥grade 3 AEs with CBR1 (rs998383); (iii) overall response rate with SULT1E1 (rs1881668) and GSTA2 (rs2180314); and (iv) PFS with CYP4Z1 (rs4926802) and CYP2A6 (rs28399442).

Conclusions

Exploratory associations were observed between sunitinib PK/PD with hepatic functional imaging with extensive pharmacogenomics. Further validation is required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SunitinibLiverKidney NeoplasmsAntineoplastic AgentsCarcinoma, Renal CellHumansMaleMiddle AgedFemaleAgedAdultProgression-Free SurvivalGenomicsPharmacogeneticsIndolesPyrroles

Stichwörter der Autor:innen

DMEThepatic functional imagingpharmacodynamicspharmacokineticssunitinib

Substanzen

SunitinibSU 12662Antineoplastic AgentsIndolesPyrroles

Autor:innen und Institutionen

  • Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
  • Peninsula and Southeast Oncology, Frankston, Victoria, Australia.
  • Biostatistics and Clinical Trial Centre, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

ORCID-Profile: Michael Michael

Förderung

  • National Health and Medical Research Council
  • Pfizer

Zitieren

APA

Michael, M., Toner, G. C., Ganju, V., Link, E., Thompson, M., Matera, A., Hicks, R. J., Campbell, I., Rowley, S., Karapetis, C. S., Burge, M., & Pook, D. W. (2026). The utility of genomics and functional imaging to predict sunitinib pharmacokinetics and pharmacodynamics: The predict SU study. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70431

Vancouver

Michael M, Toner GC, Ganju V, Link E, Thompson M, Matera A, et al. The utility of genomics and functional imaging to predict sunitinib pharmacokinetics and pharmacodynamics: The predict SU study. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70431

BibTeX
@article{Michael2026,
  author = {Michael, Michael and Toner, Guy C and Ganju, Vinod and Link, Emma and Thompson, Mick and Matera, Anetta and Hicks, Rodney J and Campbell, Ian and Rowley, Simone and Karapetis, Christos S and Burge, Matthew and Pook, David W},
  title = {The utility of genomics and functional imaging to predict sunitinib pharmacokinetics and pharmacodynamics: The predict SU study},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70431}
}
Kostenlos starten →